Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals (NQ: VNDA )

6.240 -0.260 (-4.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vanda Pharmaceuticals

< Previous 1 2 3 4 Next >
Vanda Pharmaceuticals: Q3 Earnings Insights
Vanda Pharmaceuticals (NASDAQ:VNDA) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization
Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S. What... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Outlook Therapeutics (NASDAQ:OTLK) shares increased by 38.49% to $3.13 during Tuesday's pre-market session. The company's market cap stands at $543.3... 
Via Benzinga
Vanda Pharmaceuticals Inc (VNDA) Q2 2021 Earnings Call Transcript
VNDA earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Vanda Pharmaceuticals: Q2 Earnings Insights
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 6.25% year... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For July 28, 2021
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.55 per share on revenue of $7.90 billion. • United... 
Via Benzinga
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
BridgeBio Pharma Stock Sees Rising Relative Strength; Still Shy Of Key Threshold
In a welcome move, biotech BridgeBio Pharma stock saw its Relative Strength Rating rise from 70 to 73 on Thursday. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
This morning 158 companies set new 52-week highs. Intriguing Points: NVIDIA (NASDAQ:NVDA) was the largest firm on a market cap basis to set a new 52-week high. The... 
Via Benzinga
Translate Bio Stock Flashes Improved Technical Strength Rating; Triple-Digit Sales Growth
Translate Bio shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Crispr Therapeutics Stock Sees Improved Relative Strength Rating
Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74. 
Via Investor's Business Daily
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
Exposures Product Safety
Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating
Cel-Sci sees its Relative Strength Rating hit the 80-plus level. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2021
Upgrades Craig-Hallum upgraded the previous rating for ShotSpotter Inc (NASDAQ:SSTI) from Hold to Buy. For the first quarter, ShotSpotter had an EPS of $0.02, compared to... 
Via Benzinga
Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
On Tuesday, Altimmune stock received a positive adjustment to its Relative Strength Rating, from 78 to 86. The biopharma stock is worth watching. 
Via Investor's Business Daily
Vanda Pharmaceuticals Inc (VNDA) Q1 2021 Earnings Call Transcript
VNDA earnings call for the period ending December 31, 2020. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.